Ericka Bagi, BSN, RN, presented “Diagnostic and Prognostic Biomarkers for Prostate Cancer” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Bagi, Ericka. “Diagnostic and Prognostic Biomarkers for Prostate Cancer.” September 21, 2023. Accessed Sep 2024. https://grandroundsinurology.com/diagnostic-and-prognostic-biomarkers-for-prostate-cancer/
Diagnostic and Prognostic Biomarkers for Prostate Cancer – Summary
Ericka Bagi, BSN, RN, discusses diagnostic and prognostic biomarkers in prostate cancer, emphasizing their pivotal role in guiding personalized treatment decisions and improving patient outcomes.
Bagi analyzes biomarker tests, such as prostate-specific antigen (PSA) and its derivatives, PSA density, and PSA velocity. Further, she discusses biomarkers such as the Gleason score, genomic classifiers (e.g., Oncotype DX, Prolaris), and molecular markers (e.g., TMPRSS2-ERG fusion). Information from these tests is instrumental in tailoring treatment plans to individual patient profiles, optimizing therapeutic strategies, and minimizing unnecessary interventions for low-risk patients.
Novel biomarkers, including circulating tumor cells (CTCs), exosome-based markers, and genetic mutations (e.g., BRCA mutations), hold promise for further refining risk assessment and treatment selection. These biomarkers provide complementary information to traditional clinical and imaging evaluations, enabling a comprehensive understanding of disease biology and response to therapy.
Ericka Bagi underscores the importance of integrating biomarker testing into routine clinical practice to enhance diagnostic accuracy, prognostic certainty, and therapeutic efficacy in prostate cancer management. Standardized protocols for biomarker assessment and interpretation ensure consistency across healthcare settings, facilitating evidence-based decision-making and improving patient care outcomes.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Ericka Bagi is a Senior Medical Science Liaison at MDxHealth. She has over 10 years of nursing experience, with over 8 years specializing in prostate cancer and surgery. She was previously a Nurse Navigator at Urology of Indiana. She built and maintained Artemis Fusion Prostate Biopsy program, assisting in over 2,500 prostate biopsies. She also created and instituted programs for Active Surveillance, HIFU, Space Oar, and Hereditary Genetics. Ericka also has worked as a surgical nurse prior to becoming as Nurse Navigator and first assisted numerous urological surgical procedures such as da Vinci Radical Prostatectomy, Cystectomy, Nephrectomy, etc. Ericka has hosted quarterly pathology reviews with urologists and radiologists who were a part of Artemis Fusion Biopsy Program. Lastly she co-developed molecular diagnostic and imaging pathways for the early detection of clinically significant prostate cancer.
